Diabetes drug Lyxumia effective in late-stage trials

10/2/2012 | Reuters

Data from late-stage studies show that Sanofi's diabetes drug candidate Lyxumia, or lixisenatide, can reduce blood glucose and slow food passage after a meal when combined with other diabetes treatments, the drugmaker said. Lyxumia is awaiting European approval and will be submitted for FDA approval in December.

View Full Article in:


Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Stop Loss Sales Executive, (Southern Region)
Indigo Insurance Services
Multiple Locations, SL_Multiple Locations
Health Services Researcher
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO